Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CERC-501 · 1 trial · 1 indication
Latency (in minutes and seconds) to time of first cigarette smoked during the delay period
Number of cigarettes smoked during the self administration period
| Arm | Type | Description |
|---|---|---|
| CERC-501 | EXPERIMENTAL | Administered orally once daily, 15mg daily, 8 days. |
| Placebo | PLACEBO_COMPARATOR | Administered orally daily, 8 days. |
| Name | Type | Description |
|---|---|---|
| CERC-501 | DRUG | CERC-501 |
| Placebo | DRUG | Placebo |
Inclusion Criteria: 1. Provides written informed consent and agrees to complete required clinic visits 2. Male or female 21 to 60 years of age inclusive 3. Body mass index (BMI) 18.5 to 40 kg/m2 inclusive 4. Heavy Smokers 5. Currently not seeking smoking cessation therapy 6. In otherwise good gener...
CERC-501 is an investigational small molecule being studied for smoking cessation. It is in Phase 2 clinical development for the treatment of smoking, a psychiatric therapeutic area. The drug is not approved and remains under investigation.
CERC-501 is a small molecule developed for smoking cessation. Its specific molecular target has not been disclosed in available information, so its mechanism of action is not detailed here.
CERC-501 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The drug is currently in Phase 2 clinical trials for smoking cessation.
CERC-501 is in Phase 2 clinical development. It is an investigational drug for smoking cessation and has not been approved by regulatory authorities. One Phase 2 trial has been completed.
CERC-501 has one completed Phase 2 trial, NCT02641028, titled "A Study in a Human Laboratory Model of Smoking Behavior." This randomized, double-blind, placebo-controlled trial enrolled 71 participants in the United States and studied smoking behavior.
CERC-501 is the primary name for this investigational drug. No alternative names have been associated with it in available information.